{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T03:24:46Z","timestamp":1789269886186,"version":"build-2803163510"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,7,20]],"date-time":"2021-07-20T00:00:00Z","timestamp":1626739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,7,20]],"date-time":"2021-07-20T00:00:00Z","timestamp":1626739200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1007\/s00280-021-04331-0","type":"journal-article","created":{"date-parts":[[2021,7,20]],"date-time":"2021-07-20T16:03:26Z","timestamp":1626797006000},"page":"723-729","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Impact of pharmacist consultation at clinical trial inclusion: an effective way to reduce drug\u2013drug interactions with oral targeted therapy"],"prefix":"10.1007","volume":"88","clinical-trial-number":[{"clinical-trial-number":"nct04025541","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9404-5044","authenticated-orcid":false,"given":"Fanny","family":"Leenhardt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Alexandre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Severine","family":"Guiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephane","family":"Pouderoux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Beaujouin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald","family":"Lossaint","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Philibert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Evrard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Jacot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,20]]},"reference":[{"key":"4331_CR1","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/s1553-7250(08)34091-4","volume":"34","author":"DD Cousins","year":"2008","unstructured":"Cousins DD, Heath WM (2008) The National Coordinating Council for medication error reporting and prevention: promoting patient safety and quality through innovation and leadership. Jt Comm J Qual Patient Saf 34:700\u2013702. https:\/\/doi.org\/10.1016\/s1553-7250(08)34091-4","journal-title":"Jt Comm J Qual Patient Saf"},{"key":"4331_CR2","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.1016\/S0140-6736(19)32608-X","volume":"394","author":"A Ballerie","year":"2019","unstructured":"Ballerie A, Alix L, Bajeux E, J\u00e9go P, Lescoat A, Hue B (2019) The collaboration of clinical pharmacists and physicians for medication safety. Lancet 394:2240. https:\/\/doi.org\/10.1016\/S0140-6736(19)32608-X","journal-title":"Lancet"},{"key":"4331_CR3","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1136\/ejhpharm-2015-000745","volume":"23","author":"E Dufay","year":"2016","unstructured":"Dufay E, Morice S, Dony A, Baum T, Doerper S, Rauss A et al (2016) The clinical impact of medication reconciliation on admission to a French hospital: a prospective observational study. Eur J Hosp Pharm Sci Pract 23:207\u2013212. https:\/\/doi.org\/10.1136\/ejhpharm-2015-000745","journal-title":"Eur J Hosp Pharm Sci Pract"},{"key":"4331_CR4","unstructured":"EMA (2015) Good practice guide on recording, coding, reporting and assessment of medication errors. https:\/\/www.ema.europa.eu\/en\/documents\/regulatory-procedural-guideline\/good-practice-guide-recording-coding-reporting-assessment-medication-errors_en.pdf"},{"key":"4331_CR5","unstructured":"WHO World Health Organization (2014) The high5s project\u2014standard operating protocol for medication reconciliation. https:\/\/www.who.int\/patientsafety\/implementation\/solutions\/high5s\/h5s-sop.pdf"},{"key":"4331_CR6","doi-asserted-by":"publisher","first-page":"39","DOI":"10.2147\/IPRP.S169727","volume":"8","author":"E Patel","year":"2019","unstructured":"Patel E, Pevnick JM, Kennelty KA (2019) Pharmacists and medication reconciliation: a review of recent literature. Integr Pharm Res Pract 8:39\u201345. https:\/\/doi.org\/10.2147\/IPRP.S169727","journal-title":"Integr Pharm Res Pract"},{"key":"4331_CR7","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1111\/bcp.13017","volume":"82","author":"E Almanasreh","year":"2016","unstructured":"Almanasreh E, Moles R, Chen TF (2016) The medication reconciliation process and classification of discrepancies: a systematic review. Br J Clin Pharmacol 82:645\u2013658. https:\/\/doi.org\/10.1111\/bcp.13017","journal-title":"Br J Clin Pharmacol"},{"key":"4331_CR8","doi-asserted-by":"publisher","first-page":"580","DOI":"10.2146\/ajhp151052","volume":"74","author":"KE McGahey","year":"2017","unstructured":"McGahey KE, Weiss GJ (2017) Reviewing concomitant medications for participants in oncology clinical trials. Am J Health-Syst Pharm 74:580\u2013586. https:\/\/doi.org\/10.2146\/ajhp151052","journal-title":"Am J Health-Syst Pharm"},{"key":"4331_CR9","unstructured":"FDA\u00a0 (2020) Center for drug evaluation and research, labeling (207103Orig1s002, Palbociclib) 2016. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2016\/207103Orig1s002.pdf. Accessed 17 Nov 2020"},{"key":"4331_CR10","doi-asserted-by":"publisher","first-page":"S1057","DOI":"10.1016\/j.annonc.2020.08.1489","volume":"31","author":"L Malifarge","year":"2020","unstructured":"Malifarge L, Deppenweiler M, Italiano A, Lortal B (2020) 1842P Impact of medication reconciliation for patients enrolled in oncology early phases clinical trials: a drug-drug interactions retrospective study. Ann Oncol 31:S1057. https:\/\/doi.org\/10.1016\/j.annonc.2020.08.1489","journal-title":"Ann Oncol"},{"key":"4331_CR11","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.conctc.2017.03.003","volume":"6","author":"KA Redic","year":"2017","unstructured":"Redic KA, Skyles A, Zaccardelli J (2017) Potential role of a pharmacist to enhance medication-related aspects of clinical trials conducted in a dedicated clinical research unit. Contemp Clin Trials Commun 6:55\u201357. https:\/\/doi.org\/10.1016\/j.conctc.2017.03.003","journal-title":"Contemp Clin Trials Commun"},{"key":"4331_CR12","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1186\/s12885-018-5076-0","volume":"18","author":"LA Marcath","year":"2018","unstructured":"Marcath LA, Coe TD, Hoylman EK, Redman BG, Hertz DL (2018) Prevalence of drug-drug interactions in oncology patients enrolled on National Clinical Trials Network oncology clinical trials. BMC Cancer 18:1155. https:\/\/doi.org\/10.1186\/s12885-018-5076-0","journal-title":"BMC Cancer"},{"key":"4331_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2020.113438","volume":"188","author":"F Leenhardt","year":"2020","unstructured":"Leenhardt F, Gracia M, Perrin C, Muracciole-Bich C, Marion B, Roques C et al (2020) Liquid chromatography\u2013tandem mass spectrometric assay for the quantification of CDK4\/6 inhibitors in human plasma in a clinical context of drug-drug interaction. J Pharm Biomed Anal 188:113438. https:\/\/doi.org\/10.1016\/j.jpba.2020.113438","journal-title":"J Pharm Biomed Anal"},{"key":"4331_CR14","doi-asserted-by":"publisher","first-page":"175883591983386","DOI":"10.1177\/1758835919833867","volume":"11","author":"M Bellet","year":"2019","unstructured":"Bellet M, Ahmad F, Villanueva R, Valdivia C, Palomino-Doza J, Ruiz A et al (2019) Palbociclib and ribociclib in breast cancer: consensus workshop on the management of concomitant medication. Ther Adv Med Oncol 11:175883591983386. https:\/\/doi.org\/10.1177\/1758835919833867","journal-title":"Ther Adv Med Oncol"},{"key":"4331_CR15","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1002\/cpdd.356","volume":"6","author":"W Sun","year":"2017","unstructured":"Sun W, Klamerus KJ, Yuhas LM, Pawlak S, Plotka A, O\u2019Gorman M et al (2017) Impact of acid-reducing agents on the pharmacokinetics of palbociclib, a weak base with pH-dependent solubility, with different food intake conditions. Clin Pharmacol Drug Dev 6:614\u2013626. https:\/\/doi.org\/10.1002\/cpdd.356","journal-title":"Clin Pharmacol Drug Dev"},{"key":"4331_CR16","unstructured":"EMA (2020) R\u00c9SUM\u00c9 DES CARACT\u00c9RISTIQUES DU PRODUIT, Ibrance n.d. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/ibrance-epar-product-information_fr.pdf. Accessed 23 March 2020"},{"key":"4331_CR17","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1007\/s40262-018-0711-0","volume":"58","author":"M Tod","year":"2019","unstructured":"Tod M, Goutelle S, Bleyzac N, Bourguignon L (2019) A generic model for quantitative prediction of interactions mediated by efflux transporters and cytochromes: application to P-glycoprotein and cytochrome 3A4. Clin Pharmacokinet 58:503\u2013523. https:\/\/doi.org\/10.1007\/s40262-018-0711-0","journal-title":"Clin Pharmacokinet"},{"key":"4331_CR18","unstructured":"Drugs.com (2020) Drug Interaction Report\u202f: Palbociclib information from Drugs.com. DrugsCom n.d. https:\/\/www.drugs.com\/interactions-check.php?drug_list=1717-0,3602-0. Accessed 23 March 2020"},{"key":"4331_CR19","doi-asserted-by":"publisher","first-page":"607","DOI":"10.2146\/ajhp170449","volume":"75","author":"DL Hertz","year":"2018","unstructured":"Hertz DL, Siden R, Modlin J, Gabel LL, Wong SF (2018) Drug interaction screening in SWOG clinical trials. Am J Health-Syst Pharm 75:607\u2013612. https:\/\/doi.org\/10.2146\/ajhp170449","journal-title":"Am J Health-Syst Pharm"},{"key":"4331_CR20","doi-asserted-by":"publisher","first-page":"e23127","DOI":"10.1200\/JCO.2019.37.15_suppl.e23127","volume":"37","author":"F Correard","year":"2019","unstructured":"Correard F, Blanc-l\u00e9ger F, Roux C, Lobrot F, Pinguet F, Pourrat X et al (2019) Complementary medicine and cancer: a French multicenter survey. J Clin Oncol 37:e23127\u2013e23127. https:\/\/doi.org\/10.1200\/JCO.2019.37.15_suppl.e23127","journal-title":"J Clin Oncol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-021-04331-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-021-04331-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-021-04331-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,16]],"date-time":"2021-08-16T06:04:03Z","timestamp":1629093843000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-021-04331-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,20]]},"references-count":20,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["4331"],"URL":"https:\/\/doi.org\/10.1007\/s00280-021-04331-0","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,20]]},"assertion":[{"value":"11 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study used the clinical data collected in the framework of a prospective and monocentric pharmacokinetics-toxicity correlation study (Clinicaltrials.gov identifier NCT04025541) carried out at the Institut du Cancer de Montpellier (ICM), France, in accordance with Good Clinical Practice (GCP). Committee for the protection of persons: Positive opinion issued on September 4, 2018; IdRCPN\u00b02018-A00064-51.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All patient included in the clinical trial have signed the consent form.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Not concerned.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Permission to reproduce material from other sources"}}]}}